WHI Observational Study: Cardiovascular death in women with hypertension but no history of CVD on monotherapy CVD death Diuretic, HR (95% CI) ACE inhibitor,

Slides:

Advertisements

Similar presentations

NHANES III Prevalence of Hypertension* According to BMI

Advertisements

Hypertension Diagnosis and Treatment  Based on JNC 7 – published in 2003  Goal: BP

6 / 5 / RENAL DISEASE OUTCOMES IN HYPERTENSIVE PATIENTS STRATIFIED INTO 3 GROUPS BY BASELINE GLOMERULAR FILTRATION RATE (GFR) ALLHAT.

Combination Therapy for Hypertension Summary and Comment by Harlan M. Krumholz, MD, SM Published in Journal Watch Cardiology December 3, 2008Journal Watch.

1 Antihypertensive Trial Outcome Differences: Diuretic vs. Calcium Channel Blocker Compared to participants assigned to the diuretic, those assigned to.

Avoiding Cardiovascular Events through COMbination Therapy in Patients LIving with Systolic Hypertension The First Outcomes Trial of Initial Therapy With.

Pai JK et al. N Engl J Med 2004; 351: Relative CHD risk by increasing baseline CRP plasma levels,* relative to CRP

To assess the prognostic value of variability in home-measured blood pressure (BP) and heart rate (HR) in a general population. Objective: Methods: BP.

ALLHAT Antihypertensive and Lipid-Lowering Treatment to Prevent Heart Attack Trial JAMA 2002;288:

ALLHAT 6/5/ CARDIOVASCULAR DISEASE OUTCOMES IN HYPERTENSIVE PATIENTS STRATIFIED BY BASELINE GLOMERULAR FILTRATION RATE (3 GROUPS by GFR)

VBWG Growth in heart disease, 2000–2050 Deaths Population Foot DK et al. J Am Coll Cardiol. 2000;35:

1 ALLHAT Antihypertensive Trial Results by Baseline Diabetic Status January 28, 2004.

JNC 7 血壓分期. 血壓分期 JNC 7 ： 1. 增加高血壓前期 2.Stages 2 及 3 高血壓被合併 JNC 7, 2003.

6/5/ CARDIOVASCULAR DISEASE OUTCOMES IN HYPERTENSIVE PATIENTS STRATIFIED BY BASELINE GLOMERULAR FILTRATION RATE (4 GROUPS by GFR) ALLHAT.

Therapeutics Conference. Fluid Resuscitation Early correction of fluid deficit is essential in hypovolemic shock to prevent decline in tissue perfusion.

Saleem Jessani 1, Rasool Bux 1 and Tazeen H. Jafar 1,2. 1 Aga Khan University, Karachi, Pakistan 2 Duke-NUS Graduate Medical School, Singapore Socio-demographic.

Date of download: 6/28/2016 Copyright © 2016 American Medical Association. All rights reserved. From: Urinary Sodium and Potassium Excretion and Risk of.

Date of download: 7/1/2016 From: Time-Updated Systolic Blood Pressure and the Progression of Chronic Kidney Disease: A Cohort Study Ann Intern Med. 2015;162(4):

Prognostic Value of B-Type Natriuretic Peptides in Patients With Stable Coronary Artery Disease: The PEACE Trial Torbjørn Omland, MD, PHD, MPH, Marc S.

Estimated 24-h urinary excretion of sodium and composite of cardiovascular death.. Figure 3. Estimated 24-h urinary excretion of sodium and composite of.

What should the Systolic BP treatment goal be in patients with CKD?

Copyright © 2011 American Medical Association. All rights reserved.

Health April 13, 2017.

Baseline characteristics and effectiveness results

Copyright © 2015 American Medical Association. All rights reserved.

Copyright © 2007 American Medical Association. All rights reserved.

Copyright © 2007 American Medical Association. All rights reserved.

Comparison of baseline characteristics in participants who subsequently had an incident cardiovascular event or new-onset diabetes in the Prospective.

Association of blood lipids with AF

by Hiroshi Yatsuya, Aaron R. Folsom, Alvaro Alonso, Rebecca F

Hazard ratio (HR) for mortality for a 1-kg/m2 increase in body mass index (BMI) across the range of baseline BMI among patients with acute ischemic stroke.

Association of low eosinophil and lymphocyte counts with different initial presentations of cardiovascular disease over the first 6 months ‘Low eosinophils’

Progress and Promise in RAAS Blockade

Mean BP from initial visit to four years

Creatinine clearance (mL/min) n All-cause mortality (%)

Prevalence of statin and beta-blocker use by clinical presentation

Drug Rate ratio 95% CI Thiazide diuretics 1.0 Reference ACE inhibitors

Outcome Relative risk with beta blockers 95% CI Stroke –1.30

Franklin SS, et al. Circulation 2009;119:243-50

Dileep Raman et al. JACEP 2017;3:

Relative risk of hypertension by quintiles of lipids (mg/dL)

OR (95% CI) for CHD associated with inflammatory markers before and after adjustment for established risk factors. OR (95% CI) for CHD associated with.

Incidence of all renal events according to achieved BP levels, adjusted for age, gender, duration of diabetes, glycosylated hemoglobin, currently treated.

Avoiding Cardiovascular Events through COMbination Therapy in Patients LIving with Systolic Hypertension The First Outcomes Trial of Initial Therapy With.

OR (95% CI) for CHD associated with inflammatory markers in all participants and in subsets of non-users of statins or non-users of aspirin therapy. OR.

NAFLD (nonalcoholic fatty liver disease), CVD, and type 2 diabetes: Details of the study design Targher G et al. Diabetes Care 2007;30:

Connie W. Tsao et al. JCHF 2016;4:

Baseline Characteristics of the Subjects*

DENERHTN Trial design: Patients with resistant hypertension were randomized to renal denervation plus standardized stepped-care antihypertensive treatment.

Managing Blood Pressure

Baseline Lipid Parameters and Characteristics Among 3110 Men According to Quintiles of Total Cholesterol Ruben O. Halperin et al, Hypertension 2006;47;45-50.

Baseline characteristics of older women (NHS I), younger women (NHS II), and men (HPFS) with a history of hypertension according to thiazide use Eric N.

Forest plot showing the association between center-level characteristics and death-censored technique failure after adjusting for age, sex, race, body.

Adjusted ORs of AF within 30 days after bereavement with specific characteristics versus non-bereaved with the same characteristics. * *The vertical dashed.

Connie W. Tsao et al. JCHF 2016;4:

Associations between type of MI and incident HF

Number of patients who would have benefitted from addition of ACE inhibitor (ACEi), beta blockers (BB) or optimal therapy (one or both of ACEi and BB)

Expected value of perfect implementation: population net health benefit and maximum justifiable investment if all patients who were eligible received beta.

Adjusted HRs (95% CIs) for all-cause mortality associated with BMI by smoking status in men and women and by CHD, type 2 diabetes, and cancer status at.

Adjusted ORs of AF according to time since bereavement versus non-bereaved in a population from Denmark between 1995 and * *ORs are adjusted for.

Adjusted HRs (95% CIs) for all-cause mortality associated with body fat percentage by smoking status in men and women and by CHD, type 2 diabetes, and.

Recommendations for the treatment of confirmed hypertension in people with diabetes. *An ACE inhibitor (ACEi) or angiotensin receptor blocker (ARB) is.

Prevalence of cardiovascular risk factors compared with the Canadian population. Prevalence of cardiovascular risk factors compared with the Canadian population.

Risk of venous thromboembolism by ABO blood type, factor V Leiden R506Q and prothrombin G20210A mutations among individuals in the Copenhagen General.

Adjusted all-cause (A) and CVD (B) mortality HRs (95% CIs) for IFG, IGT, NDM, and KDM compared with NGT according to ethnic group. Adjusted all-cause (A)

The combined effects of low sodium and the DASH diet according to baseline blood pressure. The combined effects of low sodium and the DASH diet according.

Adjusted ORs of increasing severity of heartburn at follow-up in reference to baseline from model adjusted for BMI category, CVD history, BDI score >11,

HR for mortality in ischemic heart disease.

HR for myocardial infarction.

The cumulative incidence curve demonstrated that patients with a sub-optimal LDL-C response to statin therapy were associated with a higher risk of CVD.

Presentation transcript:

WHI Observational Study: Cardiovascular death in women with hypertension but no history of CVD on monotherapy CVD death Diuretic, HR (95% CI) ACE inhibitor, HR Beta blocker, HR Calcium channel blocker, HR p Fully adjusted* 1.00 0.97 (0.60-1.56) 0.83 (0.47-1.85) 1.55 (1.02-2.35) 0.04 *Adjusted for age and race/ethnicity, plus smoking, high cholesterol levels requiring medication, body mass index, physical activity, use of hormone therapy, and diabetes Wassertheil-Smoller S et al. JAMA 2004; 292:2849-2859.

WHI Observational Study: Cardiovascular death in women with hypertension but no history of CVD by antihypertensive combination therapy CVD death Beta blocker plus diuretic, HR (95% CI) ACE inhibitor plus diuretic, HR (95% CI) Diuretic plus calcium channel blocker, HR (95% CI) ACE inhibitor plus calcium channel blocker, HR (95% CI) p Fully adjusted 1.00 0.87 (0.43-1.68) 1.85 (1.02-3.36) 1.14 (0.49-2.65) 0.05 Women without diabetes 0.65 (0.28-1.48) 2.16 (1.16-4.03) 0.64 (0.19-2.22) 0.002 Women without diabetes and baseline SBP <140 mm Hg 0.79 (0.25-2.48) 2.53 (1.01-6.36) 0.62 (0.08-5.01) 0.06 Wassertheil-Smoller S et al. JAMA 2004; 292:2849-2859.